Halozyme Therapeutics HALO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $150.05M— | —— | $175.23M+6.1% | $165.16M+39.9% | $118.1M-13.8% | ||
| $4.22M+27.8% | $3.3M+22.4% | $2.7M0.0% | $2.7M+0.5% | $2.69M+1.3% | ||
| $16.64M+0.4% | $16.57M+36.3% | $12.16M0.0% | $12.16M+13.9% | $10.67M-6.9% | ||
| -$3.43M— | —— | -$27.35M-486% | $7.09M+148% | $2.86M— | ||
| —— | $12.18M0.0% | $12.18M0.0% | $12.18M0.0% | $12.18M— | ||
| $19.55M-78.4% | $90.48M+205% | $29.7M+153% | $11.72M+406% | -$3.83M-117% | ||
| -$27.38M-45.8% | -$18.78M-1,806% | $1.1M-92.4% | $14.54M+2,381% | $586K-92.4% | ||
| -$24.92M-174% | $33.85M+572% | -$7.16M+75.9% | -$29.69M-422% | $9.22M-81.6% | ||
| $9.11M— | —— | $20.32M-43.7% | $36.07M+622% | $5M+189% | ||
| $29.51M+26.2% | $23.38M+31.6% | $17.76M0.0% | $17.76M0.0% | $17.76M0.0% | ||
| $2.25M+15.1% | $1.95M+5.0% | $1.86M+0.3% | $1.85M+0.3% | $1.85M+0.1% | ||
| $180.08M-17.8% | $219.03M+22.6% | $178.6M+79.1% | $99.71M-35.3% | $154.22M-13.6% | ||
| $3.74M+162% | $1.43M-52.9% | $3.03M+93.9% | $1.56M+64.5% | $950K-68.9% | ||
| $8.85M— | $0-100% | $4.96M-95.2% | $102.76M-26.4% | $139.64M+171% | ||
| $9M-96.7% | $273.38M+30.4% | $209.6M+10.8% | $189.11M+277% | $50.17M-40.3% | ||
| —— | $71.22M0.0% | $71.22M0.0% | $71.22M0.0% | $71.22M— | ||
| -$2.88M+99.6% | -$741.79M-468% | $201.61M— | —— | -$90.42M— | ||
| $1.61M— | —— | —— | —— | $3.32M— | ||
| -$1.61M— | —— | -$22.4M+92.5% | -$298.97M-8,902% | -$3.32M+98.7% | ||
| $175.59M— | —— | $357.8M+413% | -$114.47M-289% | $60.48M+257% | ||
| —— | $2.86M0.0% | $2.86M0.0% | $2.86M0.0% | $2.86M+8.2% | ||
| —— | $33.66M0.0% | $33.66M0.0% | $33.66M0.0% | $33.66M+67.0% | ||
| $30K-68.8% | $96K-73.1% | $357K-68.5% | $1.13M-33.6% | $1.71M-28.7% | ||
| $2.25M+15.1% | $1.95M+5.0% | $1.86M+0.3% | $1.85M+0.3% | $1.85M+0.1% | ||
| $29.51M+26.2% | $23.38M+31.6% | $17.76M0.0% | $17.76M0.0% | $17.76M0.0% | ||
| -$214K+21.0% | -$271K-59.4% | -$170K+33.9% | -$257K-1.6% | -$253K-24.0% | ||
| -$3.43M— | —— | -$27.35M-486% | $7.09M+148% | $2.86M— | ||
| $9.11M— | —— | $20.32M-43.7% | $36.07M+622% | $5M+189% | ||
| —— | $71.22M0.0% | $71.22M0.0% | $71.22M0.0% | $71.22M— | ||
| —— | $71.94M0.0% | $71.94M0.0% | $71.94M0.0% | $71.94M— | ||
| $710K— | —— | —— | —— | $0— | ||
| —— | $180.56M0.0% | $180.56M0.0% | $180.56M0.0% | $180.56M+82.6% | ||
| $9M— | —— | $209.6M+10.8% | $189.11M+277% | $50.17M— | ||
| —— | $1.37M0.0% | $1.37M0.0% | $1.37M0.0% | $1.37M— | ||
| $170K— | —— | —— | $637K+571% | $95K-79.2% | ||
| —— | $33.66M0.0% | $33.66M0.0% | $33.66M0.0% | $33.66M+67.0% | ||
| $176.34M-19.0% | $217.6M+23.9% | $175.57M+78.9% | $98.15M-36.0% | $153.27M-12.6% | ||
| $176.34M-19.0% | $217.6M+23.9% | $175.57M+78.9% | $98.15M-36.0% | $153.27M-12.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
